Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HBM9036 in Chinese Subjects With Moderate and Severe Dry Eye
NCT04633213Phase 3Completed
- Sponsor
- Harbour BioMed
- Start
- Feb 2021
- Primary completion
- Aug 2022
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in dry eye syndrome (DED) comparing HBM9036 0.25% Ophthalmic Solution with Placebo Ophthalmic Solution (2 arms). Primary endpoint: Change from baseline in total corneal staining scores (upper, central and lower cornea) of the study eye at 8 weeks. Started Feb 2021; status: completed.
02
Drugs
tanfanercept
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on NCT04633213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04633213.